Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Consumer OTC Drugs

Inverness Finds New Revenue Stream In Settlement With Pfizer

This article was originally published in The Tan Sheet

  • News
  • The Tan Sheet

Executive Summary

Inverness Medical Innovations' settlement of pregnancy test patent litigation with Pfizer may lead to future collaborations between the firms related to the contended technology

You may also be interested in...



Pfizer, Inverness Agree To Work Together On Digital e.p.t. Pregnancy Test

Pfizer will soon sell a digital version of its e.p.t. pregnancy test kit after Inverness Medical Innovations consents to let the firm's Warner-Lambert subsidiary use Inverness' patented technology employed in its Clearblue Easy Digital product

Pfizer, Inverness Agree To Work Together On Digital e.p.t. Pregnancy Test

Pfizer will soon sell a digital version of its e.p.t. pregnancy test kit after Inverness Medical Innovations consents to let the firm's Warner-Lambert subsidiary use Inverness' patented technology employed in its Clearblue Easy Digital product

Pfizer, Inverness Agree To Work Together On Digital e.p.t. Pregnancy Test

Pfizer will soon sell a digital version of its e.p.t. pregnancy test kit after Inverness Medical Innovations consents to let the firm's Warner-Lambert subsidiary use Inverness' patented technology employed in its Clearblue Easy Digital product

Table

View full table

Related Content

HBW Insight
Pink Sheet
HBW Insight
Pink Sheet

Topics

Tags:
Consumer OTC Drugs
Latest Headlines

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

Partisan Politics Returns To US FDA Congressional Oversight

GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows

Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development

See All
UsernamePublicRestriction

Register

PS095583

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By